200 related articles for article (PubMed ID: 25526234)
21. Duration of anti-resorptive therapy for osteoporosis.
Adler RA
Endocrine; 2016 Feb; 51(2):222-4. PubMed ID: 26433739
[TBL] [Abstract][Full Text] [Related]
22. The Good and the Bad About the 2017 American College of Physicians Osteoporosis Guidelines.
Lagari V; Gavcovich T; Levis S
Clin Ther; 2018 Jan; 40(1):168-176. PubMed ID: 29196083
[TBL] [Abstract][Full Text] [Related]
23. Long-term use of bisphosphonates in osteoporosis.
Watts NB; Diab DL
J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
[TBL] [Abstract][Full Text] [Related]
24. Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference.
Beard MK
Curr Med Res Opin; 2012 Jan; 28(1):141-7. PubMed ID: 22103779
[TBL] [Abstract][Full Text] [Related]
25. Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women.
Sambrook P
Clin Interv Aging; 2007; 2(1):65-72. PubMed ID: 18044076
[TBL] [Abstract][Full Text] [Related]
26. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P
J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505
[TBL] [Abstract][Full Text] [Related]
27. Low incidence of anti-osteoporosis treatment after hip fracture.
Rabenda V; Vanoverloop J; Fabri V; Mertens R; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
J Bone Joint Surg Am; 2008 Oct; 90(10):2142-8. PubMed ID: 18829912
[TBL] [Abstract][Full Text] [Related]
28. What is a 'failure' of bisphosphonate therapy for osteoporosis?
Carey JJ
Cleve Clin J Med; 2005 Nov; 72(11):1033-9. PubMed ID: 16315442
[TBL] [Abstract][Full Text] [Related]
29. Oral bisphosphonate compliance and persistence: a matter of choice?
Silverman SL; Schousboe JT; Gold DT
Osteoporos Int; 2011 Jan; 22(1):21-6. PubMed ID: 20458571
[TBL] [Abstract][Full Text] [Related]
30. The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment.
Guañabens N; Moro-Álvarez MJ; Casado E; Blanch-Rubió J; Gómez-Alonso C; Díaz-Guerra GM; Del Pino-Montes J; Valero Díaz de Lamadrid C; Peris P; Muñoz-Torres M;
Endocrine; 2019 Jun; 64(3):441-455. PubMed ID: 30963388
[TBL] [Abstract][Full Text] [Related]
31. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
Josse R; Khan A; Ngui D; Shapiro M
Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
[TBL] [Abstract][Full Text] [Related]
32. Bisphosphonates for the prevention and treatment of osteoporosis.
Maraka S; Kennel KA
BMJ; 2015 Sep; 351():h3783. PubMed ID: 26333528
[TBL] [Abstract][Full Text] [Related]
33. Patient adherence to osteoporosis medications: problems, consequences and management strategies.
Papaioannou A; Kennedy CC; Dolovich L; Lau E; Adachi JD
Drugs Aging; 2007; 24(1):37-55. PubMed ID: 17233546
[TBL] [Abstract][Full Text] [Related]
34. What is new in the treatment of steroid-induced osteoporosis?
Liu RH; Werth VP
Semin Cutan Med Surg; 2007 Dec; 26(4):203-9. PubMed ID: 18395668
[TBL] [Abstract][Full Text] [Related]
35. [New development in bisphosphonate treatment. Fracture prevention by bisphosphonates].
Hosoi T
Clin Calcium; 2009 Jan; 19(1):11-8. PubMed ID: 19122260
[TBL] [Abstract][Full Text] [Related]
36. Current approaches to osteoporosis treatment.
Lim SY; Bolster MB
Curr Opin Rheumatol; 2015 May; 27(3):216-24. PubMed ID: 25760281
[TBL] [Abstract][Full Text] [Related]
37. [The successful development of bisphosphonates in the therapy of osteoporosis].
Fassbender WJ; Stumpf UC; Kurth A
Med Klin (Munich); 2006 Jun; 101 Suppl 1():6-14. PubMed ID: 16826363
[TBL] [Abstract][Full Text] [Related]
38. Loss of treatment benefit due to low compliance with bisphosphonate therapy.
Penning-van Beest FJ; Erkens JA; Olson M; Herings RM
Osteoporos Int; 2008 Apr; 19(4):511-7. PubMed ID: 17874028
[TBL] [Abstract][Full Text] [Related]
39. Adherence and persistence: impact on outcomes and health care resources.
Reginster JY
Bone; 2006 Feb; 38(2 Suppl 2):S18-21. PubMed ID: 16443406
[TBL] [Abstract][Full Text] [Related]
40. Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?
McClung M
Clin Obstet Gynecol; 2013 Dec; 56(4):743-8. PubMed ID: 24177063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
